首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1804866

醫藥品·生物科技產業的銷售契約 (2020～2025年)

Distribution Deals in Pharmaceuticals and Biotechnology 2020-2025

出版日期: 2025年09月01日 | 出版商:

Current Partnering | 英文 300+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告提供了 2020 年至 2025 年製藥和生物技術產業分銷協議的詳細資訊。它提供了雙方已宣布的分銷協議中的付款條款，並提供了有關付款條款和其他交易條款的寶貴見解。

主要優勢

本報告提供讀者以下主要優勢：

了解 2020 年及以後的合約趨勢
查看經銷協議
基準分析：了解交易的市場價值
財務條款
合約目錄：依公司（A-Z）、治療領域、技術類型
按價值劃分的主要合約
識別最活躍的承包商
識別每筆交易的資產和條款
存取合約文件：深入了解合約結構
盡職調查：評估與合作夥伴協調合約條款
節省數百小時的研究時間

調查範圍

生物製藥分銷合約趨勢
分銷合約結構概述
製藥和生物技術領域分銷合約記錄目錄
按價值劃分的主要分銷合約
最活躍的經銷承包商
主要經銷合作夥伴資源

可利用契約的清單:

企業 (A～Z)
契約總額
治療領域
技術類型

銷售契約定義
2020年以後的銷售契約趨勢
- 2020～2025年的銷售契約:各年度
- 2020～2025年的銷售契約:各開發階段
- 2020～2025年的銷售契約:各業界
- 2020～2025年的銷售契約:各治療領域
- 2020～2025年的銷售契約:各技術類型
- 2020～2025年的銷售契約:最活躍的各企業
- 純分銷協議的屬性
- 混合安排中分銷協議的屬性
為了調整合作夥伴，使之有作用銷售契約的配合措施

第3章銷售契約結構:概要

銷售契約結構
更廣泛的銷售契約的一環的銷售權

第4章主要銷售契約

首位銷售契約:各金額

第5章最活躍的銷售契約企業:前25家

最活躍的銷售契約企業:前25家

第6章含契約名錄的銷售契約

包含從2020年到2025年契約的銷售契約
契約名錄
契約名錄- 各企業銷售契約 (A-Z)
契約名錄- 各治療領域的銷售契約
契約名錄- 各技術類型的銷售契約
關於Biopharma Research
目前聯盟
目前契約
Current Partnering的最近報告標題

簡介目錄

Product Code: CP2052

Distribution Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter distribution deals.

Fully revised and updated, the report provides details of distribution deals from 2020 to 2025.

The report provides access to distribution deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of distribution deals announced since 2020 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual distribution contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of distribution dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in distribution as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of distribution deals.

Chapter 4 provides a review of the leading distribution deals since 2020. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active distribution dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of distribution deals organized by company A-Z, therapy, technology and industry type signed and announced since 2020 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the distribution deal.

The deal directory includes a comprehensive listing of all distribution deals announced since 2020. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in distribution dealmaking since 2020.

In conclusion, this report provides everything a prospective dealmaker needs to know about distribution alliances.

Key benefits

Distribution Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

Understand deal trends since 2020
Browse distribution deals
Benchmark analysis - identify market value of transactions
Financials terms
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Distribution Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the distribution trends and structure of deals entered into by leading biopharma companies worldwide.

Distribution Deals in Pharmaceuticals and Biotechnology includes:

Trends in distribution dealmaking in the biopharma industry
Overview of distribution deal structure
Directory of distribution deal records covering pharmaceutical and biotechnology
The leading distribution deals by value
Most active distribution dealmakers
The leading distribution partnering resources

In Distribution Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

Company A-Z
Headline value
Therapeutic area
Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Distribution Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for distribution deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the rights granted or optioned?
What rights are granted by the agreement?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are intellectual property rights handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in distribution dealmaking

2.1. Introduction
2.2. Definition of distribution deals
2.3. Trends in distribution deals since 2020
- 2.3.1. Distribution dealmaking by year, 2020-2025
- 2.3.2. Distribution dealmaking by phase of development, 2020-2025
- 2.3.3. Distribution dealmaking by industry sector, 2020-2025
- 2.3.4. Distribution dealmaking by therapy area, 2020-2025
- 2.3.5. Distribution dealmaking by technology type, 2020-2025
- 2.3.6. Distribution dealmaking by most active company, 2020-2025
- 2.3.7. Attributes of pure distribution deals
- 2.3.8. Attributes of distribution in multi-component deals
2.4. Aligning partners to make the distribution agreement work